Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib Cover

.blurhash-client-img { display: none !important; }

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib

Radiology and Oncology

Volume 52 (2018): Issue 2 (June 2018)

By: Ana Ursula Gavric, Janja Ocvirk and Polona Jaki Mekjavic

Open Access

|Jan 2018

Authors

Ana Ursula Gavric

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

Janja Ocvirk

Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Polona Jaki Mekjavic

polona.jaki@guest.arnes.si

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

DOI: https://doi.org/10.2478/raon-2018-0002 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 213 - 219

Submitted on: Oct 4, 2017

|

Accepted on: Nov 20, 2017

|

Published on: Jan 24, 2018

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

metastatic malignant melanoma,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2018 Ana Ursula Gavric, Janja Ocvirk, Polona Jaki Mekjavic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 52 (2018): Issue 2 (June 2018)Next article